Brief Summary

Individual patient expanded access requests may be considered for patients who have no other treatment options

Detailed Description

Expanded access may provide access for treatment prior to approval by the local regulatory agency. For full details, please visit the link provided.

Available
Individual Patients
X-linked Hypophosphatemia
Tumor-Induced Osteomalacia

Biological: Burosumab
Other Name: UX023
Other Name: Crysvita®
Other Name: KRN23

Eligibility Criteria

Inclusion Criteria:

-

Exclusion Criteria:

-

Eligibility Gender
All
Contacts

Early Access
1-415-483-8800
EarlyAccess@ultragenyx.com

Ultragenyx Pharmaceutical Inc
Kyowa Kirin Co., Ltd.
NCT Number
Keywords
Expanded Access
Compassionate Use
XLH
TIO
MeSH Terms
Osteomalacia
Familial Hypophosphatemic Rickets
Hypophosphatemia